A market leader in Japan with a 130-year history, Santen is paving new roads in the US and China. Peter Sallstig, MD, MBA, Santen’s CMO and global head of product development division sat down with OIS Podcast host Paul Karpecki, OD, to lay out the blueprint. 

In less than 30 minutes, you’ll hear about the products and business strategies that will help Santen compete in these markets at a high level. And that’s not all.

A true global leader, Dr. Sallstig speaks five languages fluently. Using one of them, he discussed Santen’s long-term plan, the strength of Santen’s leadership, and its latest developments. Here’s a glimpse:

In 2020, Santen acquired topical ophthalmic specialist Eyevance Pharmaceuticals. In a similar vein, Santen recently launched Verkazia, a topical immunomodulator approved for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. Santen also has multiple products for glaucoma in its pipeline. Tune in to discover:

• Dr. Sallstig’s path to becoming Santen’s CMO, which began in primary care and merged into ophthalmology and industry.
• The importance of good leadership and other product development lessons he’s learned along the way.
• The current vision for Santen, both globally and within the US market.
• The story of Verkazia, the first and only topical immunomodulator approved for VKC.
• Advice for others interested in pursuing an executive career.

Click “play” to listen.